Discussion
Kyverna Therapeutics’ experimental cell therapy KYV-101, now called mivocabtagene autoleucel (miv-cel), was associated with rapid, sustained symptom improvements in all seven participants with hard-to-treat generalized myasthenia gravis (gMG) in a clinical trial.